The AZ-002 Phase IIa clinical trial is an in-clinic proof of concept study. It is a four-center, randomized, double-blind, placebo-controlled evaluation of 49 patients with panic disorder. The primary aim of the clinical trial was to assess the safety and efficacy of a single dose of AZ-002 in treating a pharmacologically-induced panic attack.
Differences versus placebo in the intensity and the duration of a panic attack, measured at multiple time points during the study using psychological and physiological measurements, will be used to assess the safety and efficacy of AZ-002. Alexza projects that the initial results will be reported before the end of second quarter of 2008.
AZ-002 is an inhalation product candidate being developed for the acute treatment of panic attacks associated with panic disorder. AZ-002 is being developed through Symphony Allegro, a development collaboration formed between Alexza and Symphony Capital in 2006.